Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s): MDNAF

Healthcare Biotechnology

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.

TSX:MDNA - Post by User

Medicenna Therapeutics Corp

Bullboard Posts

Post by BioTechGuru3314on Jun 25, 2019 1:11am

329 Views

Post# 29858894

The science is VERY sound

Extremely optimistic regarding MDNA55 and their preclinical pipeline.

Based on their results thus far, the Phase 2b data due in November is likely to be very positive in a very unfortunate patient population with limited options. I could easily see a BIG buyout from big Pharma once final phase 2b results are in !

Bullboard Posts

One of the strongest contenders to lead Canada’s cannabis market